

ASX Announcement

13 May 2022

GENETIC SIGNATURES APPOINTS NON-EXECUTIVE DIRECTOR

Genetic Signatures Limited (**ASX:GSS**), an Australian-based global molecular diagnostics company, is pleased to announce that Ms Caroline Waldron has been appointed as a new Non-Executive Director from 13 May 2022.

Ms Waldron is currently a director of Resimac Group Limited (ASX:RMC) and AMA Group Limited (ASX:AMA).

Her executive experience includes leadership roles in law, HR, marketing, risk and internal audit gained from ASX100 and bluechip organisations. Ms Waldron's formal training is in law, and she has been admitted to the Bar of England and Wales, and the courts of various jurisdictions including in Australia and New Zealand.

"I am pleased to welcome Ms Waldron to the board where her unique combination of skills and multi-sector experience will complement our board's strong business, commercialisation, and molecular diagnostics experience," says Dr Nick Samaras, Genetic Signatures' Non-Executive Chairman.

"Ms Waldron's experience in digital transformation, customer centricity and marketing will assist Genetic Signatures sustain the strong global growth of our proprietary **3base® EasyScreen™** testing platform," added Dr John Melki, Director and Chief Executive Officer.

In accepting the appointment Ms Waldron said, "Genetic Signatures is a dynamic emerging Australian biotechnology company that is increasingly realising its commercial potential and I look forward to helping it deliver on its strategy and growth on the world stage."

Approved by Genetic Signatures' Board of Directors

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki

Chief Executive Officer

john.melki@geneticsignatures.com

T: +61 (0)2 9870 7580

Peter Manley

Chief Financial Officer

peter.manley@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base™**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the **EasyScreen™** brand. Genetic Signatures' proprietary MDx **3base™** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.